Research

The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study

Adam M Deane1,2, Marianne J Chapman1,2, Robert JL Fraser3,4, Carly M Burgstad5, Laura K Besanko3 and Michael Horowitz4

1University of Adelaide, Discipline of Anaesthesia and Intensive Care, North Terrace, Adelaide, 5000, South Australia, Australia
2Royal Adelaide Hospital, Department of Intensive Care, North Terrace, Adelaide, 5000 South Australia, Australia
3Investigation and Procedures Unit, Repatriation General Hospital, Daws Road, Daw Park, 5041, South Australia, Australia
4University of Adelaide, Discipline of Medicine, North Terrace, Adelaide, 5000 South Australia, Australia
5Royal Adelaide Hospital, Department of Gastroenterology, North Terrace, Adelaide, 5000 South Australia, Australia

Corresponding author: Adam M Deane, adam.deane@adelaide.edu.au

Abstract

Introduction Hyperglycaemia occurs frequently in the critically ill, affects outcome adversely, and is exacerbated by enteral feeding. Furthermore, treatment with insulin in this group is frequently complicated by hypoglycaemia. In healthy patients and those with type 2 diabetes, exogenous glucagon-like peptide-1 (GLP-1) decreases blood glucose by suppressing glucagon, stimulating insulin and slowing gastric emptying. Because the former effects are glucose-dependent, the use of GLP-1 is not associated with hypoglycaemia. The objective of this study was to establish if exogenous GLP-1 attenuates the glycaemic response to enteral nutrition in patients with critical illness induced hyperglycaemia.

Methods Seven mechanically ventilated critically ill patients, not previously known to have diabetes, received two intravenous infusions of GLP-1 (1.2 pmol/kg/min) and placebo (4% albumin) over 270 minutes. Infusions were administered on consecutive days in a randomised, double-blind fashion. On both days a mixed nutrient liquid was infused, via a post-pyloric feeding catheter, at a rate of 1.5 kcal/min between 30 and 270 minutes. Blood glucose and plasma GLP-1, insulin and glucagon concentrations were measured.

Results In all patients, exogenous GLP-1 infusion reduced the overall glycaemic response during enteral nutrient stimulation (AUC30–270 min GLP-1 (2077 ± 144 mmol/l min) vs placebo (2568 ± 208 mmol/l min); P = 0.02) and the peak blood glucose (GLP-1 (10.1 ± 0.7 mmol/l) vs placebo (12.7 ± 1.0 mmol/l); P<0.01). The insulin/glucose ratio at 270 minutes was increased with GLP-1 infusion (GLP-1 (9.1 ± 2.7) vs. placebo (5.8 ± 1.8); P = 0.02) but there was no difference in absolute insulin concentrations. There was a transient, non-sustained, reduction in plasma glucagon concentrations during GLP-1 infusion (t = 30 minutes GLP-1 (90 ± 12 pmol/ml) vs. placebo (104 ± 10 pmol/ml); P<0.01).

Conclusions Acute, exogenous GLP-1 infusion markedly attenuates the glycaemic response to enteral nutrition in the critically ill. These observations suggest that GLP-1 and/or its analogues have the potential to manage hyperglycaemia in the critically ill.

Trial Registration Australian New Zealand Clinical Trials Registry number: ACTRN12609000093280.
need for a therapy to manage hyperglycaemia in enterally fed patients without the risk of hypoglycaemia [6].

Exogenous administration of the incretin hormone, glucagon-like peptide-1 (GLP-1), has been shown to normalise blood glucose concentrations both in healthy patients and those with type 2 diabetes [7]. This occurs as a result of stimulation of insulin secretion, suppression of glucagon release and slowing of gastric emptying [7,8]. Because the former effects are glucose dependent, the use of GLP-1 does not appear to be associated with hypoglycaemia [9]. The effect of GLP-1 on glycaemia in enterally fed critically ill patients has hitherto not been evaluated. The primary aim of this study was to determine whether exogenous GLP-1 attenuates the glycaemic response to small intestinal nutrient infusion in critically ill patients not previously known to be diabetic.

Materials and methods

Subjects

Seven critically ill adult patients (four males, three females, age range 28 to 76 years), predicted to remain mechanically ventilated for more than 48 hours, were studied. Exclusion criteria included pregnancy, pre-existing diabetes, contraindication to enteral feeding or post-pyloric catheter insertion, and previous surgery on the oesophagus, stomach or duodenum.

The study was approved by the Human Ethics Committee of the Royal Adelaide Hospital and performed according to the Australian National Health and Medical Research Committee guidelines for the conduct of research involving unconscious persons. Written, informed consent was obtained from the next of kin.

Study protocol

Patients were studied on two consecutive days, in which they received intravenous GLP-1 or placebo in a randomised, double-blind fashion. Twelve hours prior to the study, a naso-duodenal feeding catheter was inserted and confirmed via abdominal x-ray. On each study day enteral feeding was ceased at least four hours prior to the commencement of the study. Exogenous insulin (Actrapid, Novo-Nordisk, Copenhagen, Denmark) infusion was ceased at least two hours before the commencement of the study drug. Patient weight was provided by a relative and/or estimated by a dietician. Randomisation and reconstitution of synthetic GLP-1-(7–36) amide (Merck Biosciences, Melbourne, Australia), as a solution in 4% albumin, was performed by the Royal Adelaide Hospital Pharmacy department. The study investigators were blinded to each infusion, which were concealed in a glass bottle covered by black plastic. Both GLP-1 (1.2 pmol/kg/min) and placebo (4% albumin) were infused at a rate of 1 ml/min via a central venous catheter for 270 minutes (i.e. t = 0 to 270 min). At t = 30 minute Ensure® (Abbott, Melbourne, Australia), a mixed nutrient liquid (64% carbohydrate, 1 kcal/ml), was delivered continuously into the small intestine at a rate of 1.5 ml/min for four hours (i.e. t = 30 to 270 min). An arterial blood sample was obtained every 15 minutes for measurement of blood glucose and at timed intervals for measurements of plasma insulin, GLP-1 and glucagon concentrations.

Data analysis

Blood glucose was measured at the bedside using a portable glucometer (Medisense Optimum, Abbott, Melbourne, Australia). Blood was collected, separated by centrifugation and the resulting plasma was stored at -70° until assayed for hormone concentrations. Plasma insulin was measured by ELISA (Diagnostics Systems Laboratories, Webster, Texas, USA) with an inter-assay coefficient of variation (CV) of 6.2%. Total plasma GLP-1 (GLPIT-36HK Linco Research, St. Charles, Missouri, USA) and glucagon (Siemens Medical Solution Diagnostics, Berkeley, California, USA) concentrations were measured by radioimmunoassay, with a CV of 9.2% and 12%, respectively.

Statistical analysis

Data are presented as mean ± standard error of the mean. Area under the curve (AUC) was calculated using the trapezoidal rule. The number of patients required to establish a glucose lowering effect of GLP-1 was based on power calculations derived from our previous work [8]. The ratios of insulin/glucose were calculated, as described previously [10]. Statistical analyses were performed using SPSS (Version 15.0, Chicago, Illinois, USA). Distribution and sensitivity analysis, using nonparametric analyses, allowed parametric testing of data. The difference between intervention and placebo was assessed using paired samples; Student’s paired t-test and repeated measures analysis of variance. Data were evaluated for potential carry over effect. The null hypothesis was rejected at the 0.05 significance.

Results

The study was well tolerated in all patients. Patient details are shown in Table 1.

Blood glucose

Blood glucose concentrations are shown in Figure 1. There was no difference in baseline blood glucose concentration prior to each infusion (t = 0 min GLP-1 7.5 ± 0.4 mmol/l vs. placebo 7.6 ± 0.6 mmol/l; P = not significant (NS)). Prior to the commencement of the small intestinal nutrient infusion (t = 30 min) GLP-1 had no effect on blood glucose. On both days, there was an increase in blood glucose concentration in response to intra-duodenal nutrient infusion (t = 180 min GLP-1 9.3 ± 0.6 mmol/l; placebo 12.2 ± 0.9 mmol/l; P < 0.01 for both). GLP-1 markedly attenuated the rise in blood glucose (e.g. t = 60 min GLP-1 7.5 ± 0.5 mmol vs. placebo 9.5 ± 0.8 mmol; P < 0.01), peak blood glucose (GLP-1 10.1 ± 0.7 mmol/l vs. placebo 12.7 ± 1.0 mmol/l; P < 0.01) and decreased the overall glycaemic response (AUC30–270 min)
GLP-1 2077 ± 144 mmol/l min vs. placebo 2568 ± 208 mmol/l min; \( P = 0.02 \).

**Plasma insulin**

Plasma insulin and insulin:glucose ratio is shown in Figures 2a and 2b. There was no difference in plasma insulin concentration at baseline. Plasma insulin increased in response to intraduodenal nutrient (e.g. \( t = 270 \) min GLP-1 79 ± 21 mU/l and placebo 61 ± 17 mU/l; \( P < 0.03 \) compared with fasting concentration for both days). At 270 minutes, the insulin/glucose ratio was greater with GLP-1 (GLP-1 9.1 ± 2.7 vs. placebo 5.8 ± 1.8; \( P = 0.02 \)); however, there was no difference in absolute plasma insulin concentrations throughout the entire study period (AUC\(_{0–270\text{ min}}\) GLP-1 16,203 ± 5193 mU/l min vs. placebo 14,434 ± 4561 mU/l min; \( P = \text{NS} \)).

**Plasma GLP-1**

Plasma GLP-1 concentrations are shown in Figure 2c. Fasting plasma GLP-1 concentrations were similar between groups (\( t = 0 \) min GLP-1 36 ± 10 pmol/l vs. placebo 38 ± 11 pmol/l; \( P = \text{NS} \)). Exogenous GLP-1 markedly increased plasma GLP-1 concentration within 30 minutes (\( t = 30 \) min GLP-1 124 ± 15 pmol/l vs. placebo 43 ± 9 pmol/l; \( P < 0.01 \)) and throughout the infusion period (AUC\(_{0–270\text{ min}}\) GLP-1 31,659 ± 4203 pmol/l min) vs. placebo 10,399 ± 2508 pmol/l min; \( P < 0.01 \)). During GLP-1 infusion, steady state concentrations were achieved after 30 minutes (\( t = 30 \) min plasma GLP-1 124 ± 15 pmol/l vs. \( t = 90 \) min plasma GLP-1 131 ± 13 pmol/l; \( P = \text{NS} \)).

**Plasma glucagon**

Plasma glucagon concentrations are shown in Figure 2d. Fasting glucagon concentrations were similar between study days (\( t = 0 \) min GLP-1 106 ± 14 pmol/ml vs. placebo 102 ± 13 pmol/ml; \( P = \text{NS} \)). There was a decrease in plasma glucagon from baseline during GLP-1 infusion (\( t = 30 \) min GLP-1 90 ± 12 pmol/ml vs. placebo 104 ± 10 pmol/ml; \( P < 0.01 \)), which was non-sustained (AUC\(_{0–270\text{ minutes}}\) GLP-1 22,786 ± 6040 pmol/ml min vs. placebo 25,830 ± 2644 pmol/ml min; \( P = \text{NS} \)).
Discussion

This is the first study to evaluate the effect of exogenous GLP-1 infusion on the glycaemic response to enteral nutrition during critical illness. Given the need to avoid hyperglycaemia and hypoglycaemia in critically ill patients, an assessment of the effect of exogenous GLP-1 is of considerable interest.

The dose of GLP-1 used in the current study was based on a previous study in which infusion of GLP-1 at 1.2 pmol/kg/min achieved fasting normoglycaemia, and was well tolerated in postoperative patients with type 2 diabetes [11]. Hyperglycaemia in critically ill patients, not previously known to have diabetes, is associated with poorer outcomes than in patients with pre-existing diabetes [12]. Hence, we chose to study the effect of exogenous GLP-1 in these patients. Insulin infusions were ceased two hours before the commencement of the study to ensure clearance of exogenous insulin. Given the short plasma half life of GLP-1 [13] carry over effects were not anticipated or observed, and a crossover protocol was an appropriate study design. The nutrient type and load were selected on a feeding regimen which aims to deliver 25 kcal/kg/day of mixed nutrient liquid [14]. Accordingly, 1.5 kcal/min of Ensure® was administered. Hyperglycaemia in critical illness is believed to reflect inadequate insulin secretion, hepatic and peripheral insulin resistance, and an increase in the counter-regulatory hormones cortisol, catecholamines, glucagon and growth hormone [15]. Only plasma insulin and glucagon concentrations were measured, as GLP-1 is not known to alter the secretion of the other counter-regulatory hormones and the study was designed to establish proof of concept [9].

Exogenous GLP-1 slows gastric emptying substantially [8] and this may be the dominant mechanism by which GLP-1 reduces postprandial glycaemic excursions [16]. Hence, the magnitude of glucose lowering by GLP-1 is likely to be even greater during gastric, rather than small intestinal, nutrient administration [17]. However, delayed gastric emptying occurs in approximately 50% of critically ill patients and, when marked, may lead to under-nutrition, gastro-oesophageal reflux and pulmonary aspiration [18]. Given the above considerations it was appropriate to initially determine whether GLP-1 attenuates the glycaemic response to small intestinal, rather than intra-gastric, nutrient. Whether GLP-1 will slow gastric emptying further in critically ill patients remains to be determined.

It should be recognised that nutrient-induced hyperglycaemia was only attenuated, and not suppressed completely by GLP-1. This may potentially reflect an insufficient GLP-1 dose, and larger doses are known to be well tolerated [19]. As discussed, given the effect of GLP-1, to slow gastric emptying, it is possible that the magnitude of glucose lowering will be greater during gastric feeding. However, some critically ill patients may also have inadequate β-cell reserve to compensate for the disordered hormone milieu even at larger doses and/or during gastric feeding. Given the complexity and severity of disordered glucose metabolism in the critically ill, and an ongoing requirement for nutrition, it is anticipated that exogenous GLP-1 may achieve normoglycaemia only in specific subgroups of patients. However, this study establishes the concept that GLP-1 as sole therapy, or in combination with insulin, has the potential to manage hyperglycaemia in the critically ill.

We elected to evaluate the effects of an acute GLP-1 infusion in a relatively small, heterogeneous cohort of critically ill patients studied at various times after their admission. This limitation should be recognised and may have been of greater relevance if the study outcome had been negative, rather than positive. Although our study only measured the effect of a
short-term infusion, it is likely that the glucose-lowering effect would persist for the entire period of GLP-1 administration [20]. Furthermore, we speculate that longer-term GLP-1 infusion may result in less glycaemic variability than the current approach to insulin therapy, because of its effects on both insulin and glucagon. An additional limitation is the inconclusive evidence regarding insulin stimulation and glucagon suppression. Although there were no observed differences in absolute insulin concentrations during the entire GLP-1 infusion, there was an increase in the insulin/glucose ratio and transient suppression of glucagon secretion. Moreover, the number of subjects included was based on power calculations for a glucose-lowering effect and the study may have been underpowered to establish effects on insulin and glucagon over the entire study period. Given the positive outcome of this study, additional studies are required to further elucidate the mechanisms underlying the effects of GLP-1 and determine the optimal dose and duration of treatment in the critically ill.

Conclusions
This study establishes that exogenous GLP-1 infusion limits the peak blood glucose, and markedly attenuates the overall glycaemic response, during small intestinal feeding, in non-diabetic critically ill patients. Given exogenous GLP-1 may improve the safety and efficacy of glycaemic control in this group, further investigation into its potential use is warranted.

Key messages
- The effects of exogenous GLP-1 are glucose dependent, thus the use of GLP-1 is not associated with hypoglycaemia.
- Exogenous GLP-1 markedly attenuates the glycaemic response to small intestinal nutrient in critically ill patients.
- Exogenous GLP-1 is a novel therapy to treat hyperglycaemia and further investigation into its potential use in the critically ill is warranted.

Competing Interests
The authors declare that they have no competing interests.

Authors' contributions
AD was the main contributor to study design, acquisition, analysis and interpretation of the data and drafting the manuscript. MJC and RF contributed to study conception and revision of manuscript. CB and LKB were responsible for data acquisition and analysis and contributed to revision of manuscript. MH was the main contributor to study conception and participated in drafting the manuscript. All authors read and approved the final manuscript.

Authors' information
AD is an intensivist enrolled as a PhD student at the University of Adelaide. His thesis studies the effects of incretin hormones in critically ill patients. He is supervised by MJC, RJF and MH. The results were presented in abstract form at the 2008 meeting of the Australian New Zealand Intensive Care Society.

Acknowledgements
AD is supported by a University of Adelaide/Royal Adelaide Hospital Co-funded Dawes Scholarship. This study was supported by a research grant from the Australian New Zealand College of Anaesthetists. The authors are grateful for the assistance provided by Ms. Sharon Yap (Department of Pharmacy Royal Adelaide Hospital) for randomisation, preparation and blinding of study drug, Ms Judith Wishart (Discipline of Medicine University of Adelaide) for analysis of insulin and GLP-1 concentrations and Mr Kris Tan (Department of Endocrinology Royal Prince Alfred Hospital Sydney) for analysis of glucagon concentrations.

References
1. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002, 87:978-982.
2. Berghe G van den, Wouters P, Weevers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367.
3. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Grundling M, Oppert M, Grond S, Oltöff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnert E, Kienzl H, Hartog C, Tanazon N, Loeflner C, Reiffen K, German Competence Network Sepsis (SepNet): Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139.
4. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Buse J, Bigger JT, Buse J, Cushman WC, Gennuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WJ: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
5. Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P: Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. J Parenter Enteral Nutr 2003, 27:355-373.
6. Preiser JC, Devos P: Clinical experience with tight glucose control by intensive insulin therapy. Crit Care Med 2007, 35:S503-507.
7. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
8. Little TJ, Pillichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C: Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006, 91:1916-1923.
9. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinaemic, stepped hyperglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87:1239-1246.
10. Meier JJ, Gethmann A, Nauck MA, Gotze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ: The glucagon-like peptide-1 metabolite GLP-1(1–36) amide reduces postprandial glycaemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 2006, 290:E1118-1123.
11. Meier JJ, Weyhe D, Michaela M, Senkal M, Zunftbol V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B: Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004, 32:849-851.
12. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Hegarty C, Bailey M: Blood glucose concentration and outcome of critical
illness: the impact of diabetes. *Crit Care Med* 2008, 36:2249-2255.

13. Vilsboll T, Agerso H, Krarup T, Holst JJ: Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. *J Clin Endocrinol Metab* 2003, 88:220-224.

14. Stapleton RD, Jones N, Heyland DK: Feeding critically ill patients: what is the optimal amount of energy? *Crit Care Med* 2007, 35:S535-540.

15. Marik PE, Raghavan M: Stress-hyperglycemia, insulin and immunomodulation in sepsis. *Intensive Care Med* 2004, 30:748-756.

16. Horowitz M, Nauck MA: To be or not to be—an incretin or enterogastrone? *Gut* 2006, 55:148-150.

17. Meier JJ, Kemmeries G, Holst JJ, Nauck MA: Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. *Diabetes* 2005, 54:2212-2218.

18. Deane A, Chapman MJ, Fraser RJ, Bryant LK, Burgstad C, Nguyen NQ: Mechanisms underlying feed intolerance in the critically ill: Implications for treatment. *World J Gastroenterol* 2007, 13:3909-3917.

19. Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Uerdt K, Ziemer G, Haring HU, Gallwitz B, Holst JJ: Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. *Am J Cardiol* 2008, 102:646-647.

20. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. *Lancet* 2002, 359:824-830.
